News

Under the deal, Liaison will deliver its data services to customers in the healthcare industry on ClearDATA’s HIPAA-compliant cloud platform. The deal will see Liaison become a referral

The new patent will extend coverage to include a significantly broader gamut of chemical compounds, which the company might develop as immune-modulating drugs targeting an inflammatory pathway involved

Under the deal, Yabao secured exclusive rights to develop and commercialize LS-008 in China while Le Sun retains majority of exclusive rights in all other markets. Both the

The contract includes performing studies on the vaccine that has been licensed from the Public Health Agency of Canada, to move it closer to human clinical trials. The

Currently, the company is developing TRV734 to optimize analgesia while reducing on-target gastrointestinal and central nervous system adverse effects through its new biased ligand mechanism at the mu-opioid

The studies were conducted by Professor Paul Quax, Ph.D., and Yaël Nossent, Ph.D., of the Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center

Study 067-EG-005 evaluated the area under the curve (AUC) and the maximum or peak plasma concentration (Cmax) of Egalet-001 100 mg versus the same dose of MS Contin

The study demonstrates an association between a specific immune response generated by AE37 and improved overall survival. The compound is being developed by Antigen Express, Inc., a wholly-owned

The DAVA portfolio is well-positioned for continued strong financial performance with its existing commercial products and attractive near-term pipeline, and is a natural fit with Endo’s U.S. generics